| Stereochemistry | RACEMIC |
| Molecular Formula | C28H31NO5 |
| Molecular Weight | 461.5494 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)C(=O)OC2=CC=C(C=C2OC(=O)C3=CC=C(C)C=C3)C(O)CNC(C)(C)C
InChI
InChIKey=FZGVEKPRDOIXJY-UHFFFAOYSA-N
InChI=1S/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3
Bitolterol is a beta 2-adrenergic agonist. Since it in itself is biologically inactive, bitolterol is considered a pro-drug. When administered it is activated within the lung by esterase hydrolysis to the active compound colterol catecholamine N-t-butyl-arterenol. Bitolterol was marked under the name tornalate and was indicated to prevent and treat of reversible bronchospasm associated with asthma or chronic obstructive pulmonary diseases. But that drug was withdrawn from the market by Elan Pharmaceuticals in 2001.
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Acute Bronchospasm: adults and children older than 12 yr of age: oral inhalation 2 inhalations at interval of 1 to 3 min, followed by third inhalation if necessary.
Prevention of Bronchospasm: adults and children older than 12 yr of age: oral inhalation 2 inhalations every 8 h, not to exceed 3 inhalations every 6 h or 2 inhalations every 4 h.
Route of Administration:
Other
METABOLITE ACTIVE (PRODRUG)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD
